% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Reetz:281831,
author = {Reetz, Kathrin and Costa, Ana Sofia and Michels, Jennifer
and Albrecht, Milena and Moschko, Pia and Pahl, Jennifer and
Häger, Alexa and Schuckelt, Rainer and Röhrig, Rainer and
Wienströer, Jan and Flöel, Agnes and Düzel, Emrah and
Onur, Oezguer A and Grimmer, Timo and Levin, Johannes and
Frölich, Lutz and Jessen, Frank and Schulz, Jörg B},
collaboration = {Registry, German Dementia},
othercontributors = {Polivka, Dörte and Duning, Thomas and Gutschalk, Alexander
and Oberstein, Timo and Schnieder, Marlena and
Trender-Gerhard, Iris and Laske, Christoph and Dahling,
Volker and Peters, Oliver and Saur, Dorothee and Spruth,
Eike Jakob and Cheng, Bastian and Fußer, Fabian and
Bartsch, Thorsten and Glanz, Wenzel and Hausner, Lucrezia
and Riemenschneider, Matthias and Höltje, Esther and
Hellmann-Regen, Julian David Nicolai},
title = {{T}he {G}erman {D}ementia {R}egistry ({DEMREG}): study
protocol of a biomarker-based national registry for
cognitive impairment and dementia.},
journal = {Neurological research and practice},
volume = {7},
number = {1},
issn = {2524-3489},
address = {[London]},
publisher = {BioMed Central},
reportid = {DZNE-2025-01212},
pages = {80},
year = {2025},
abstract = {The German Dementia Registry (DEMREG) is a large-scale
national prospective biomarker-based study for cognitive
impairment and dementia, providing an integrated clinical
research platform for research studies.The DEMREG study
longitudinally collects demographic, clinical, genetic,
biological, and imaging data, along with risk factors and
treatment information from real-world settings.
Comprehensive clinical assessments are conducted yearly.
This extensive resource enables researchers to investigate
current diagnostic and treatment practices and explore the
complex relationships between risk factors and outcomes. The
registry is now active across 22 sites in Germany, all
members of the the German Memory Clinic Network (DNG), with
more than 500 patients recruited to date, and is expected to
include up to 1.000 patients annually.The DEMREG study
represents a large nationally harmonized cohort of detailed
real-world clinical and biological data from patients with
cognitive impairment and dementia, enabling insights into
long-term dynamics and treatment responses. This
infrastructure has the potential to foster collaborative
research and roll out healthcare innovations across
different settings in Germany. In this context, a substudy
will soon be conducted to evaluate long-term safety and
efficacy measures of the new monoclonal antibodies targeting
amyloid plaques in a clinical setting.The protocol is
registered at German Clinical Trials Register
(DRKS00027547), Date of Registration: 01.04.2022.},
keywords = {Biomarkers (Other) / Dementia (Other) / Mild cognitive
impairment (Other) / Natural history (Other) /
Neurodegeneration (Other) / Registry (Other) / Treatment
(Other)},
cin = {AG Flöel / AG Düzel / Clinical Research (Munich) / AG
Jessen},
ddc = {610},
cid = {I:(DE-2719)5000081 / I:(DE-2719)5000006 /
I:(DE-2719)1111015 / I:(DE-2719)1011102},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41146293},
pmc = {pmc:PMC12560544},
doi = {10.1186/s42466-025-00433-9},
url = {https://pub.dzne.de/record/281831},
}